The involvement o f proteases in the metastatic spread o f tumour cells and in tumour related processes, such as angiogenesis and ulceration> has been known for many decades. This chapter reviews the involvement o f one proteolytic systeinthe plas minogen activation systemin tumour progression. In recent years, many biochem ical properties of the various components o f the plasminogen activation system have become know n. These properties and the functional relationship between the com ponents are discussed in the first section. Since interfering with proteolysis by tumour cells and by newly formed endothelial cells can be an objective for future therapy, experimental tumour models have been used to study the effects of inhibitors o f plas minogen activation. The second section deals tuith this issue. Finally, the presence o f the various components of the plasminogen activation system in human tumours is reviewed. Following the availability of specific ELlSAs, antibodies and molecular probes, the content and the cellular distribution o f the components o f the plasmino gen activation system have recently been mapped in various human tumours.
binds to fibrin. t-PA is also the plasminogen activator of the adult brain195 and is thought to play a role in plas ticity and long term memory™. Also, t-PA is expressed by oocytes192 whereas u-PA is expressed by spermato cytes82. u-PA, but also t-PA, are involved in wound healing67,I78. Compared to t-PA, u-PA is thought to play a more dominant role in tissue remodeling pro cesses such as spermatogenesis83, trophoblast inva sion192, wound healing67, monocyte invasion96 and angiogenesis5, l5B, often together with u-PAR160'182 and PAI5,159. u-PA is the predominant plasminogen ac tivator involved in tumour invasive processes and me tastasis. melanomas, plasminogen is localized in stromal cells at the invasive front and in extracellular matrix (De Vries et al., J. of PathoL, 1996, in press ). Specific in hibitors of plasmin activity, a 2-macroglobulin122 and a z-antiplasmin21 are found both in (normal) plasma and in tumour tissues. Recently, it was described that a plasminogen fragment containing the kringle 1 -3 domains, named angiostatin, is capable of inhibiting tumour angiogenesis148.
Urokinase-mediated Plasminogen Activation at the Cell Surface Urokinase Receptor u-PAR Pro-u-PA can bind to cells via u-PAR, the cell surface receptor for u-PA11,222. u-PAR consists of three do mains and is linked to the membrane via a glycosylphosphatidylinositol anchor. u-PAR plays a role in plasminogen activation at the cell surface.
Plasminogen Activator Inhibitors PAI-1 and PAI-2
The two plasminogen activator inhibitors focused on in this chapter, PAI-1 and PAI-2, belong to the group of serpins: serine protease inhibitors. Other PAIs are PAI-3 and protease-nexin. Both PAI-' l and PAI-2 are ca pable of inhibiting t-PA and u-PA (reviewed in108, 202) .H it do not bind to pro-u-PA1.
PAH is found in high concentrations in the blood, where it plays a role in fibrinolysis. Uncomplexed PAI-1 becomes rapidly latent due to its instability133. PAI-1 is secreted and sticks extracellularly to vitronec tin70*106. PAI-2 is found in placental tissue54, 79 and in the blood of pregnant women4. Unlike PAM, PAI-2 is not secreted into the extracellular matrix and is loca lized mainly in the cytoplasm8.
Plasminogen
Plasminogen is the substrate for plasminogen activa tors, Cleavage of plasminogen by plasminogen activa tors forms the active enzyme plasmin. Plasminogen s to various proteins of the extracellular matrix, like fibronectin1 , laminin189, type IV collagen205 and to tetranectin32, Plasmin is capable of degrading a broad spectrum of matrix molecules. Furthermore, plasmin can convert inactive pro-collagenases into the active form. Plasmin/plasminogen binds to the cell surface of MCF7 cells36,241, but a receptor for plasmin has not been cloned. It has been reported that binding of plasminogen to cell surfaces occurs in the proximity of binding sites for t-PA (Felez 1993) or u-PA241.
Little is known about the presence of plasmin/plas minogen in cancerous tissues. In colon carcinomas, it is reported to be present in stromal cells21, 229 . Also in^
since drugs disturbing t u-PA activity can be focalized on the cell surface by binding to u-PAR11*207. Moreover, u-PA activity can be modulated by interaction of u-PA with its receptor: binding to the receptor accelerates the conversion of pro-u-PA to active u-PA on the cell surface50,177, possibly by close interaction with the receptor bound plasm in126, 206 . Binding of pro-u-PA to u-PAR is facilitated when u-PAR is glycosyl-phosphatidylinositol an chored131 and when the ligand binding site of u-PAR is glycosylated132. Upon binding to u-PAR, pro-u-PA is converted to active u-PA after cleavage by plasmin or cathepsins97. The active enzyme complex, in close proximity of plasmin/plasminogen241 can convert plas minogen to plasmin, a broad substraste protease ca pable of degrading various components of the extracellular matrix. u-PA bound to u-PAR is essential for migration of monocytes96 and tumour cells17,203. In migrating cells, u-PAR is concentrated at the ruffled edge of cells6 and in caveolae204. Caveolae, which are in the proximity of focal adhesion sites, are essen tial for u-PA mediated proteolysis at the cell surface, le specific caveolar structures abolish plasminogen activation204. u-PA163 and u-PAR137 are both expressed at focal cell-cell or cell-substrate adhesion sites. This concentration of proteases at focal adhesion sites suggests that a delicate balance ex ists between adhesion and proteolysis (see also103). In deed, adhesion molecules are found to co-localize with u-PA and u-PAR: both u-PA and u-PAR co-localize with a vp3 in cultured glioblastomas63, and u-PAR co-localizes with a vp3 in metastatic melanoma cells143. Furthermore, u-PAR is found in the same membrane fragments as (J2-integrins1,\ In cultured keratinocytes, u-PA co-ocalizes with another adhesion mole cule, E-Cadherin93. The delicate balance between adhesion and local proteolysis can be shifted towards u-PA production and invasion when adhesion is ham pered, for instance by an antibody capable of blocking ligand binging of the adhesion molecule60. In light of the delicate balance between adhesion and local pro teolysis, it is very interesting that u-PAR can perform both functions. u-PAR not only focalizes proteolysis at the cell surface by binding pro-u-PA, unoccupied u-PAR can also function as an adhesion molecule for vitronectin224,228. Furthermore, binding of u-PA to u-PAR can start a signal transduction pathway, since cy- The sequential events at the cell surface are depicted from left to right in this diagram. Pro-u-PA binds to free u-PAR, and is activated through cleaveage by plasmin or cathepsins (not shown in this diagram). The activated u-PA can convert plas minogen to plasmin and can be inhibited by PAL The u-PAR:u-PA:PAI-complex is efficiently bound and internalized by LRP. Upon internalization, u-PA and PAI are degraded and u-PAR is recycled to the cell surface. See text for details. tokeratin 8 is phosphorylated upon binding, resulting in phosphorylation and redistribution of cytokeratin filaments in human epithelial cells21* Protein tyrosine kinases are localized in the same membrane receptor complex as u-PAR13.
Active u-PA bound to u-PAR can be inactivated by PAL The u~PAR;u-PA:PAI complex, especially the u-PA:PAI part145, is recognized by LRP. The complex of u-PAR:u-PA:PAI:LRP can be internalized via a clathrin coated pit mechanism. u-PA and PAI are degraded in lysosomes and LRP and u-PAR are redistributed to the plasma membrane39,52,78. Figure 1 shows the se quential events, proposed to take place at the cell sur face.
Proteins Related to the Plasminogen Activation Process
Proteins recently described as related to the PA sys tem are the plasminogen binding protein tetranectin and members of the LDL receptor family, enabling in ternalization of (inactivated complexes of) plasmino gen activators.
Tetranectin
Tetranectin is a 68 kD protein that was purified from plasma and binds to the feringle 4 domain of plasmino gen32. Plasma of cancer patients contains significantly lower levels of tetranectin compared to age and sex matched control groups80'91,141. Tetranectin is present in a variety of cells, including monocytes142, neutro phils14 and fibroblasts33. In breast31, ovarian80 and co lon223'229 carcinomas, and in melanomas (De Vries et al., manuscript in prepation), tetranectin is present in the stroma surrounding the tumour Moreover, plasma tetranectin content and stromal immunoreactivity are a ^ m cer LRP and RAP ♦ Two proteins involved in the clearence and cellular uptake of inactivated proteases are the low density lipoprotein receptor-related protein (LRP)/a2-macroglobulin receptor(a2MR) and its receptor associated protein (RAP).
LRP is a member of the LDL receptor family107,209. LRP/a2MR is named after its homology with the low density lipoprotein receptor76 and after its capability to bind the activated forms of a 2-macroglobulin3. The gene encoding the enormous protein comprises 89 exons221, revealing a 15 kb mRNA transcript, from which a 600 kD precursor protein is translated which is cleaved into a 515 kD a-chain and an 85 kD p-chain. In addition to activated complexes of a 2-macroglobulin, many other ligands can be internalized upon binding to LRP, including ApoE and various proteins or com plexes of proteins of the plasminogen activation system (reviewed in2). t-PA can bind to LRP18 and complexes of t-PA with PAI-1 can be internalized mediated by LRP149. LRP-mediated internalization of complexes of u-PA with inhibitors occurs most efficiently when u-PA is bound to its receptor34»78»145. Gp330 (= gp600), another member of the LDL receptor family, is also capable of internalizing similar ligands as LRP, including plasminogen activators231.
RAP is a 39 kDa protein which co-purifies with LRP and other members of the LDL receptor family208 and co-localizes with LRP20, 242, RAP is restricted to the endoplasmatic reticulum and serves as a chaperone for LRP20'232. RAP can bind to LRP and thereby pre vent binding of all other known ligands, including (complexes of) plasminogen activators77,86»144,226.
Little is known about LRP and RAP expression in human tumor cell lines or in human tumors. In human tumour cell lines, it seems that LRP expression de creases with agressiveness because a) tumor cells make no or less receptor for a 2-macroglobulin when com pared to non-tumor cell lines92'187"189'220, b) mono cytes grown without the tumor promotor PMA start making LRP35, c) LRP is present in photodynamic ther apy sensitive tumor cells and not in therapy resistant cells118 and d) invasive cells make less LRP than non-invasive cells94. In human tumors, LRP has been detected in blood samples of monocyte-derived malig nant blood cells and not in other hematologic tumour cells128, it is present in glioma cells117, and is decreased or absent in malignant lymphomas129 and in hepatocel lular carcinomas64.
Plasminogen Activation in Experimental Models for Tumour Invasion and Metastasis
The process of metastasis is a complex multistep pro cess involving detachment of tumour cells from the pri mary tumour, invasion of surrounding host tissue, invasion through basal membranes, intravasation into the circulatory system, adherance to endothelium or subendothelial basement membrane and extravasa tion at a distant site and outgrowth of a secondary tu mour56. A role for proteases has been postulated in various steps of this process4 0 , 1 6 4 > 2 i 9t First, in vading tumour cells need proteases to degrade the sur rounding tissue and extracellular matrix, and secondly, proteases are required for intravasation and extravasa tion.
Various in vitro and in vivo model systems have been developed which can be employed to study and manip ulate various aspects of the complex process of meta static spread. Matrix degradation assays can be used to study the activity of proteases176,177. Invasion assays, either employing reconstituted matrix154 or chicken membranes151,153, or human placenta membranes124 or chick heart119, can be used to study true invasion of tumour cells. Finally, immunodeficient mice can be used to study experimental metastasis by injecting tumour cells in the tail vein98,99,150> 176, or, to study spontaneous metastasis, from a tumour grown upon injecting tumour cells subcutaneously98*99,176, Figure 1 illustrates that if the plasminogen activation system is indeed crucial in invasive processes and in metastasic spread of tumour cells, effects of interfer ence could prove this at two places in this process. By preventing pro-u-PA to bind to u-PAR, no cell sur face plasminogen activation can take place ( Fig. 2a ). Also, anti-catalytical substances such as anti-u-PA anti bodies, exogenously added PAI and chemical sub stances binding to the catalytical domain of u-PA can prevent plasminogen activation ( Fig. 2b) .
Disturbance of pro-u-PA binding can be achieved by molecules which can compete for the pro-u-PA binding site of u-PAR ( Fig. 2a ). Blocking the pro-u-PA binding site with an anti-u-PAR antibody demonstrated that cell surface plasminogen activation can be abol ished183. Glioblastoma cells thus treated are less inva sive in matrigel130. Also, cells of which u-PAR is saturated with the amino terminal fragment (ATF) of u-PA (e.g. not containing the catalytical site) are less invasive in matrigel98. Synthetic peptides comprising the binding domain of u-PA are able to inhibit sponta neous metastasis formation in a nude mouse metastasis model99. A most dramatic reduction of metastasis for mation from a tumour, by preventing pro-u-PA to bind to its receptor, has been shown by Crowley and co workers38. By transfecting u-PA and u-PAR producing tumour cells with ATF, an enormous reduction of me tastasis formation could be achieved. Smaller chemical substances can prevent pro-u-PA binding. Low doses of suramin, for instance, prevent cell surface binding of u-PA7. Also small 15-mer peptides could be identified as u-PAR antagonists65. Apart from blocking the cell sur face u-PAR, pro-u-PA binding can be competed with a soluble form of u-PAR, thereby preventing pro-u-PA to bind to its cell surface receptor. Addition of the soluble form of u-PAR to u-PA and u-PAR positive tumour cells can indeed inhibit invasion230. In summary, invasive properties of tumour cells can be reduced by interfer ence with u-PA:u-PAR binding. This may lead to new therapeutic approaches in the near future (reviewed in53). u-PA conjugated to a cytotoxic agent can be used to specifically destroy u-PAR positive ceils29.
The first evidence, however, that the plasminogen activation system is involved in tumour invasive and metastatic processes, arose from experiments designed to block the active u-PA ( Fig. 2b) . Antibodies blocking the catalytic site of u-PA do not block tumour growth, but can inhibit metastasis formation73,81,150. Also, in vasive properties of tumour cells can be reduced when they are pretreated with anti-catalytic antibodies against u-PA124,151. Matrix degradation of u-PA posi tive tumour cells is reduced when tumour cells are pre treated with anti u-PA antibodies 180 . In addition to anti-catalytic antibodies, the catalytic domain of u-PA can be blocked with PAI-1 or PAI-2. PAM or PAI-2 added to cultures of u-PA and u-PAR positive cells ef fectively inhibits matrix degradation180. Furthermore, HT1080 fibrosarcoma cells producing a surplus of PAI-2 are less invasive112 and melanoma cells trans fected with PAI-2 give rise to significantly less metastases in nude mice134. Smaller organic chemical substances like benzo (b) thiophene-2-carboxami-dines218 and low doses of suramin52,211 can specifi cally inhibit u-PA.
Inhibition of invasion and metastasis formation can also be obtained by reducing the amount of u-PAR available at the cell surface. Tumour cells transfected with antisense u-PAR are less tumourigenic and less invasive105»174. B16 melanoma cells transfected with the antisense construct of u-PA make fewer metas-tases240.
The other way around, actively invading and metas tasizing cells can be generated by overexpressing u~ PAR95 or by overexpressing u-PA240. In general, cell lines expressing high levels of u-PA are more invasive than cell lines expressing low levels of u-PA16,75.
All the above described experiments suggest a role for the plasminogen activation system in tumour inva sion and metastasis. The simultaneous presence of not only u-PA and u-PAR but also of PAI in highly meta static melanoma cells176, the required presence of u-PA> u-PAR and PAI-1 in highly invasive lung cancer cells116, and elevated levels of u-PA, u-PAR and PAI -simultaneously present in the same lesion44,49»179in human tumours suggests that a subtle balance of re ceptor, protease and inhibitor is required for effective invasiveness of tumour cells.
The Plasminogen Activation System in Human Tumours
Proof that the plasminogen activation system plays a role in tumour invasion and metastasis not only stems from experimental evidence, but also from direct evi dence in human tumours. Elevated levels of u-PA, u-PAR and PAI-1 compared to normal tissues are consis tently found in different tumours (e.g.23'42»44 '63*198) . Elevated levels of t-PA42'44,109,121 and PAI-244, 45, 198 are found in some tumours, but an inverse relationship (lower levels in tumour tissue compared to the normal tissue) often exists for t-PA198,237,and PAI- 215,58,21l) . Techniques with which the presence and the localiza tion of the components of the plasminogen activation system have been studied in human tumours are ELISA, immunohistochemistry and RNA in situ hybridization. With zymographic techniques, enzyme activity of t-PA and u-PA can be studied either in frozen tissue sections or in gels upon electrophoretic separation of the en zymes.
ELISA Determinations
When larger tumours are available, ELISAs specific for the various components can be performed on tissue extracts of these tumours. The level of u-PA, but also of PAI-1 and u-PAR has been shown to be of prognostic relevance. For breast cancer, for instance, the level of u-PA and PALI surpasses prognostic parameters for re lapse of the disease used so far, including lymph node involvement and estrogen receptor status46'47,57,69, 87,90. High levels of both u-PA and PAI-1 are also asso ciated with poor survival in patients with colorectal cancer61, gastric cancer140, uterine cervical cancer100 and lung cancer155,156. After the first report on the prognostic relevance of u-PAR by Ganesh and co-workers62 in colorectal cancer, high u-PAR levels were also found to be associated with poor survival in pa tients with breast cancer49,185 and squamous and large cell lung cancer156.
In addition to tumour homogenates, elevated levels of components of the plasminogen activation system were reported in body fluids such as tumour ascites and plasma. Huber et al. detected elevated levels of u-PA in plasma of patients with colorectal cancer85 and in patients with primary liver cancer84 and found that the u-PA value in combination with tumour mar ker measurement, contributed to the sensitivity of the diagnosis. High levels of a soluble form of u-PAR157, u-PA, PAI-130 and of PAI-230,113 have been detected in ascites of patients with ovarian cancer.
Immunohistochemistry and m R N A in situ Hybridization
The cellular distribution of the mRNAs and the pro teins can be studied with mRNA in situ hybridization (e.g,42,44 '63,167, 168,193) and with immunohistochemis try (e.g.44,45,68,127), respectively. From recent litera ture, it is evident that the components of the plasminogen activation system are localized in tumour cells and in various tumourassociated cell types, prob ably depending on the tumour studied. For instance, u~ PA mRNA and protein is reported to be present in tu mour surrounding fibroblasts in colon cancer68,167, whereas u-PA is localized in tumour cells42,44 and fibro blasts44 in cutaneous melanoma, and in tumour cells in squamous cell carcinoma127, 193 . The presence of the serine proteases in the tumour stroma is a phenomen on also reported for other proteases. Metalloproteases for instance, primarily localize in the stroma of tu mours136,147,1^9,233. The system may function in an autocrine way, e.g. through saturation of u-PAR by tu mour cells207. Also, paracrine mechanisms acting be tween u-PA producing stroma cells and u-PAR positive tumour cells can occur (reviewed in12). In deed, it has been shown in in vitro experiments that matrix degradation177 and invasion152 is facilitated when u-PA positive cells are mixed with u-PAR posi tive cells. Similar cooperative interactions could occur in colon cancer, where u-PAR positive tumour cells bor dering u-PA positive stroma cells could pick up u-PA from these stroma cells167. Other paracrine interac tions between tumour cells and fibroblasts are in agree ment with many reports suggesting that fibroblasts facilitate invasion186 and metastasis formation161'216. Furthermore, it has been reported that fibroblasts in tumour cell-fibroblast co-cultures are capable of indu cing the production of u-PA and metalloprotei-nases37,114.
Reports on the localization of the various compo nents in any particular tumour type are not unani mous. For instance, u-PA protein has been found in some reports in colon cancer exclusively in fibroblastic cells68,2^3, but also mainly in tumour cells135* 197. Like wise, u-PA localization has been reported in tumour cells87'90, but also exclusively in fibroblastic cells233 in mammary carcinoma.
(in situ) Zymography
Plasminogen activator activity can be detected either in a frozen section (in situ zymography)42, 44, 45, 193, 194 or in electrophoresis gels in tissue homogenates, the latter technique allowing visualization of enzymatic ac tivity of plasminogen activators complexed with PA *201. t-PA and u-PA can be distinquished through anti-catalytic antibodies anti-t-PA or u-PA, or by add ing specific t-PA or u-PA inhibitors.
t-PA in Human Tumours
When comparing the two types of plasminogen activa tors with respect to their putative role in human tumours, u-PA seems to be the most important plasminogen acti vator, since levels of t-PAare often either undetectable127, similar210 or lower23*61,138,166, 198>201 in tumour tissue compared to corresponding normal or benign tissue. Also, primary cultures of tumours210 and tumour cell lines1™ predominantly produce u-PA. In contrast to t-PA,u-PAisconsistentlyincreasedineverytumoui\Nevertheless, t-PA levels in tumour homogenates can be of par ticular prognostic interest, Yamashita et al. found that disease-free breast cancer patients had significantly low er levels of t-PA in the tumour, than patients which devel oped metastases238. Also, a low level of t-PA in colon cancer, but now in the normal mucosa, is associated with poor prognosis61.
With regard to decreased t-PA expression in human tumours, melanoma is an interesting exception. Firstly, t-PA can be isolated from cultured melanoma cells181. In vitro, melanomas make more t-PA than other tu m ours175,176, enabling the cells to degrade extracellu lar m atrix176 and to migrate through reconstituted m atrix123* Secondly, malignant melanomas and not be nign nevi express t-PA42,44,109 (see also Fig. 3a) . In uveal melanomas, t-PA is found more abundantly in tumours with less favorable prognosis45. Higher levels of t-PA have been reported in carcinoma of the cervix by Larsson et al.111. t-PA has been found in endothelial cells in benign precursor and in tumour lesions23,44s 101, consistent with a role for t-PA in fibrinolysis.
u-PA in Human Tumours
Of the various proteins of the plasminogen activa tion system, u-PA has been studied most intensely in human malignancies (reviewed in48). u-PA levels of tu mour homogenates have been found of prognostic sig nificance for various types of tumours.
The presence of u-Pa in colon cancer has been well documented. Controversy exists on where the protein is localized. It has been claimed that u-PA is localized in tumour ceiisioi,io2,i35,i97^ Others found u-PA mRNA167 and protein exclusively68, or mainly213, in the tumour stroma. Significant for the localization of u-PA and for its possible implications for meta static spread, is the finding by Tan213 that invasive parts of a tumour are u-PA positive, in contrast to pushing edges which hardly displayed u-PA positivity. On paraffin sections, Mulcahy et al. 135 found that tumour cell associated u-PA and not stromal cell associated u-PA is of prognostic relevance. Also for the u-PA/t-PA ratio a prognostic significance has been reported in colon carcinomas61. In addition, patients with colon carcinomas exhibit higher levels of u-PA in plasma85.
In breast cancer, the level of u-PA measured in tu mour extracts is a prognostic indicator for relapse of the disease15,47j 57>87"89, reviewed in196. Janicke et al. could correlate intensity of u-PA tumour cell staining to ELISA values measured in parallel samples87. Others also found u-PA in mammary carcinomas loca lized in tumour cells28,90.
In brain tumours, u-PA is detectable in high grade astrocytomas and gliomas23,63, 110,235. u-PA mRNA63,235 and protein2* 235 localize in tumour cells and in the frustrated vasculature, characteristic for these lesions.
Carcinomas of the oesophagus and the stomach con sistently exhibit higher u-PA levels compared to the normal surrounding tissue139'199. Furthermore, in gas tric carcinomas, u-PA staining of tissue sections74 and u-PA values of tum our homogenates140 yield prognostically useful information.
in bladder cancer, higher levels of u-PA is correlated with recurrent disease71,72.
u-PA is detectable in tum our cells of various types of lung cancer66, 146. Levels of u-PA are significantly high-er in these tumours compared to normal lung tissue138 and are of prognostic importance155-156.
In skin cancers, u-PA is not expressed in basal cell carcinomas, but is expressed in squamous cell carcino mas127, 193. Human cutaneous melanomas exhibit u-PA activity and immunoreactivity only in the primary tu mours and métastasés42,44,1215 whereas u-PA mRNA can also be detected in atypical nevi42. In melano mas, the protein is present in a minority of the tumour cells at the invasive front42,44 (see also Fig. 3d ) and in stromal cells at the edge of the tumour44 (see also Fig. 3e ). In uveal melanomas, u-PA is present in tu mours with worse prognosis and in metastatic le sions45. Stromal u-PA staining has also been reported in cervical cancer of the uterus100,111. Patients with lymph node involvement exhibited more prominent u-PA staining and higher antigen values in the primary tumour compared to tumours of patients without lymph node involvement100.
Abundant u-PA activity is found in mononuclear cells of leukemia patients. These high levels of u-PA could contribute to bleeding disorders, often found in patients with leukemia216.
u-PAR in Human Tumours
A role for u-PAR in tumour development has recently been described by Dan0 et al.41. Specific ELIS As for u-PAR Have only recently been developed and used to study the levels of u-PAR in human tumour tis sues62' 184. Initial studies report that high u-PAR levels are associated with poor survival in colon cancer62, in squamous cell and large cell lung cancer157, and breast cancer49.
Limited visualization of u-PAR in immunohistochemistry can be due to masking of epitopes, due to u-PA bound to u-PAR. u-PA can be released from its receptor by mild acid treatment of the tissue section, and a much brighter u-PAR staining can thus be ob tained28,43. Free u-PAR can further be visualized with autoradiography after incubation with radioactive u-PA to the cells or tissues of interest43,225.
The distribution of u-PAR mRNA and protein has been studied most extensively in tumours of the mam mary gland10,28,43'90,170. u-PAR mRNA is produced mainly by tumour associated macrophages170, but it has also been reported that the protein is predomi nantly present in tumour cells10,28,43s90? in addition to tumour-associated macrophages10. In colon can cer, u-PAR mRNA and protein is present in macro phages and tumour cells167,172, possibly basally expressed by tumour cells towards the stroma225. In astrocytomas, u-PAR mRNA is expressed by prolifer ating vessels and by tumour cells in the vicinity236. Also in gliomas, u-PAR is expressed by tumour cells63. In melanomas, u-PAR has mainly been found in tumour cells (Fig. 3b) , though also in fibroblastic cells44,4S. It has been reported for ovarian cancer how ever, that u-PAR is already present in the normal epithe lium239. Surprizing, and not consistent with a general rule that levels of u-PAR are elevated in cancer, is the absence or the reduced presence of u-PAR in all B-and T-cell malignancies and in Hodgkin's disease162.
PAI-1 in Human Tumours
It has been postulated that high levels of PAI in can cer tissue, might be beneficial for the patient, since a surplus of PAI might inactivate all plasminogen activa tors present. Apart from a rare report of decreased PAI-1 in more aggressive versus less aggressive tumours66, PAI-1 levels are consistently increased in tumours of very diverse origin. High levels of PAI-1 are associated with worse prognosis in patients with breast can cer69,89, gastric cancer74, various forms of lung can cer155 and in cervical cancer100. Furthermore, higher levels of PAI-1 in cancer tissue compared to benign or normal tissue is encountered in colorectum61,201 and the brain110. PAI-1 mRNA has been localized in endothelial cells167 in the tumour surrounding stro ma, but also in colorectal cancer cells215, in endothelial cells and tumour cells of brain tumours23,104,234, and in breast cancer cells10,90, 179. In melanomas, however, both in nude mouse xenografts of PAI-1 positive tu mour cells and in human tumours, we found that tu mour cells make the mRNA, but that the protein is deposited in the extracellular matrix44,45 (and see Fig. 3e-h) . Extracellular matrix staining was also ob served in breast cancer10.
PAI-2 in Human Tumours
At least in some tumours, the presence of PAI-2 is beneficiary for the patient's survival. Higher levels of PAI-2 is associated with good prognosis in breast can cer15,58,210. Similar tendencies exist for gastric can cer139, squamous cell carcinoma66,138, pancreatic cancer212 and ovarian cancer166, although high levels of PAI-2 have been found in the tumour cystic fluid and in peritoneal fluid of ovarian cancer pa tients24, 25,30.
In some tumours however, elevated levels of PAI-2 are associated with progression of the disease. In creased PAI-2 is seen in colon cancer compared to co lon adenomas and normal mucosa198, and is associated with poor survival in these patients61. Incidentally, PAI-2 maps to a chromosomal region which is deleted in 70% of colon cancer cases . Gliomas exhibit in creased levels of u-PA and PAI-1, but hardly any PAI-2 is found in glioma extracts110. In cutaneous mel anoma, we found PAI-2 only in advanced primary tu mours and metastases44, and in uveal melanoma, PAI-2 was only present in lesions with poor prognosis45. PAI-2 is mainly localized in tumour cells in all malignancies studied by immunohistochemistry. 
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Concluding Remarks
In the last five years, the presence and localization of components of the plasminogen activation system has been well documented for a large group of tumours. In order to clarify mechanisms of plasminogen activation in tumours of diverse origin, consensus is needed on the exact localization of the proteins. Therefore, the con troversies regarding the localization of the various components have to be cleared. Since the staining en countered in the tissue sections can be diagnostically relevant, it is important that the applied staining pro cedures are reproducible. Furthermore, complemen tary techniques should be used to confirm the results. Additional studies on the functional state of components of the plasminogen activation system in the tissue sections would be of interest. Antibodies which discriminate between inactive free pro-u-PA, ac tive u-PA bound to its receptor, u-PA inactivated by PAI, etc. might elucidate the mechanism of plasmino gen activation in tumour tissue.
Whether modulation of the plasminogen activation system can indeed be applied in human tumour ther apy remains to be seen. Knock-out mice lacking both t-PA and u-PA and knock-out mice lacking PAI-1 are viable, healthy and capable of sexual reproduc tion26,27. Apparently, back-up mechanisms exist for physiological processes like wound healing, fibrinoly sis and embryo-implantation. In analogy, one can en visage that under plasminogen activation blocked conditions other proteases might be used by the cells to invade and metastasize. Nonetheless, knowledge of the PA status of a tumour may become useful in choosing the more effective therapeutic strategy57*59.
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